Top

Published in:

01-11-2018 | Review Article

Glomerular endothelial cells versus podocytes as the cellular target in diabetic nephropathy

Authors: Silvia Maestroni, Gianpaolo Zerbini

Published in: Acta Diabetologica | Issue 11/2018

Abstract

It usually takes several years (in some cases, decades) for predisposed individuals to move from the onset of type 1 or type 2 diabetes to the development of microalbuminuria, the first sign of diabetic nephropathy. This long, complication-free, period represents the best possible moment to start a successful preventive strategy (primary prevention) aimed to avoid or at least to postpone the increase of albumin excretion rate. Prevention is based on understanding and counteracting the initial mechanisms leading to the development of the disease and unfortunately, in case of diabetic nephropathy, most of them remain unclear. Little is also known about which, among endothelial cells and podocytes, represent the first glomerular target of the complication. Selective damage of the endothelium or of the podocyte results, as a common consequence, in an increase of albumin excretion rate. Albuminuria by itself cannot therefore be of help to solve the case. Endothelium and podocytes are involved in a continuous cross-talk and by studying the impact of diabetes on this “communication” process it should be possible to obtain some information regarding the weak component of the glomerular filter. Finally, the careful investigation of the mechanisms leading to the development podocyturia, a recently identified glomerular dysfunction associated to the pathogenesis of diabetic nephropathy, could contribute to shed some more light on the very early stages of this complication.

Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D et al (2014) Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 370(16):1514–1523. https://doi.org/10.1056/NEJMoa1310799 CrossRefPubMed

Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR (1985) The changing natural history of nephropathy in type I diabetes. Am J Med 78(5):785–794CrossRef

Keen H, Chlouverakis C (1964) Urinary albumin excretion and diabetes mellitus. Lancet 2(7370):1155–1156CrossRef

Parvanova AI, Trevisan R, Iliev IP, Dimitrov BD, Vedovato M, Tiengo A et al (2006) Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes 55(5):1456–1462. https://doi.org/10.2337/db05-1484 CrossRefPubMed

De Cosmo S, Motterlini N, Prudente S, Pellegrini F, Trevisan R, Bossi A et al (2009) Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. Diabetes 58(12):2920–2929. https://doi.org/10.2337/db09-0407 CrossRefPubMedPubMedCentral

Haraldsson B, Nystrom J, Deen WM (2008) Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 88(2):451–487. https://doi.org/10.1152/physrev.00055.2006 CrossRefPubMed

Satchell SC, Braet F (2009) Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol 296(5):F947–F956. https://doi.org/10.1152/ajprenal.90601.2008 CrossRefPubMedPubMedCentral

Rostgaard J, Qvortrup K (1997) Electron microscopic demonstrations of filamentous molecular sieve plugs in capillary fenestrae. Microvasc Res 53(1):1–13CrossRef

Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG (2007) The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch 454(3):345–359. https://doi.org/10.1007/s00424-007-0212-8 CrossRefPubMedPubMedCentral

10.

Miner JH (2012) The glomerular basement membrane. Exp Cell Res 318(9):973–978. https://doi.org/10.1016/j.yexcr.2012.02.031 CrossRefPubMedPubMedCentral

11.

Timpl R (1989) Structure and biological activity of basement membrane proteins. Eur J Biochem 180(3):487–502CrossRef

12.

Grahammer F (2017) New structural insights into podocyte biology. Cell Tissue Res 369(1):5–10. https://doi.org/10.1007/s00441-017-2590-3 CrossRefPubMedPubMedCentral

13.

Grahammer F, Schell C, Huber TB (2013) The podocyte slit diaphragm–from a thin grey line to a complex signalling hub. Nat Rev Nephrol 9(10):587–598. https://doi.org/10.1038/nrneph.2013.169 CrossRefPubMed

14.

Lawrence MG, Altenburg MK, Sanford R, Willett JD, Bleasdale B, Ballou B et al (2017) Permeation of macromolecules into the renal glomerular basement membrane and capture by the tubules. Proc Natl Acad Sci USA 114(11):2958–2963. https://doi.org/10.1073/pnas.1616457114 CrossRefPubMed

15.

Obeidat M, Obeidat M, Ballermann BJ (2012) Glomerular endothelium: a porous sieve and formidable barrier. Exp Cell Res 318(9):964–972. https://doi.org/10.1016/j.yexcr.2012.02.032 CrossRefPubMed

16.

Ryan GB, Karnovsky MJ (1976) Distribution of endogenous albumin in the rat glomerulus: Role of hemodynamic factors in glomerular barrier function. Kidney Int 9(1):36–45CrossRef

17.

Holthofer H, Ahola H, Solin ML, Wang S, Palmen T, Luimula P et al (1999) Nephrin localizes at the podocyte filtration slit area and is characteristically spliced in the human kidney. Am J Pathol 155(5):1681–1687. https://doi.org/10.1016/S0002-9440(10)65483-1 CrossRefPubMedPubMedCentral

18.

Tryggvason K (1999) Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 10(11):2440–2445PubMed

19.

Schlöndorff D, Wyatt CM, Campbell KN (2017) Revisiting the determinants of the glomerular filtration barrier: what goes round must come round. Kidney Int 92(3):533–536. https://doi.org/10.1016/j.kint.2017.06.003 CrossRefPubMed

20.

Zerbini G, Bonfanti R, Meschi F, Bognetti E, Paesano PL, Gianolli L et al (2006) Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes. Diabetes 55(9):2620–2625. https://doi.org/10.2337/db06-0592 CrossRefPubMed

21.

Lorenzi M, Cagliero E, Toledo S (1985) Glucose toxicity for human endothelial cells in culture. Delayed replication, disturbed cell cycle, and accelerated death. Diabetes 34(7):621–627CrossRef

22.

Nieuwdorp M, Mooij HL, Kroon J, Atasever B, Spaan JA, Ince C et al (2006) Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 55(4):1127–1132CrossRef

23.

Deckert T, Kofoed-Enevoldsen A, Vidal P, Nørgaard K, Andreasen HB, Feldt-Rasmussen B (1993) Size- and charge selectivity of glomerular filtration in type 1 (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia 36(3):244–251CrossRef

24.

Satchell S (2013) The role of the glomerular endothelium in albumin handling. Nat Rev Nephrol 9(12):717–725. https://doi.org/10.1038/nrneph.2013.197 CrossRefPubMed

25.

Morigi M, Buelli S, Angioletti S, Zanchi C, Longaretti L, Zoja C et al (2005) In response to protein load podocytes reorganize cytoskeleton and modulate endothelin–1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol 166(5):1309–1320. https://doi.org/10.1016/S0002-9440(10)62350-4 CrossRefPubMedPubMedCentral

26.

Qi H, Casalena G, Shi S, Yu L, Ebefors K, Sun Y et al (2017) Glomerular endothelial mitochondrial dysfunction is essential and characteristic of diabetic kidney disease susceptibility. Diabetes 66(3):763–778. https://doi.org/10.2337/db16-0695 CrossRefPubMed

27.

Caramori ML, Parks A, Mauer M (2013) Renal lesions predict progression of diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol 24(7):1175–1181. https://doi.org/10.1681/ASN.2012070739 CrossRefPubMedPubMedCentral

28.

Walker F (1973) The origin, turnover and removal of glomerular basement-membrane. J Pathol 110(3):233–244. https://doi.org/10.1002/path.1711100306 CrossRefPubMed

29.

Marshall CB (2016) Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic? Am J Physiol Renal Physiol 311:F831–F843. https://doi.org/10.1152/ajprenal.00313.2016 CrossRefPubMedPubMedCentral

30.

Anil Kumar P, Welsh GI, Saleem MA, Menon RK (2014) Molecular and cellular events mediating glomerular podocyte dysfunction and depletion in diabetes mellitus. Front Endocrinol (Lausanne) 5:151. https://doi.org/10.3389/fendo.2014.00151 CrossRef

31.

Sagoo MK, Gnudi L (2018) Diabetic nephropathy: Is there a role for oxidative stress? Free Radic Biol Med 116:50–63. https://doi.org/10.1016/j.freeradbiomed.2017.12.040 CrossRefPubMed

32.

Diez-Sampedro A, Lenz O, Fornoni A (2011) Podocytopathy in diabetes: a metabolic and endocrine disorder. Am J Kidney Dis 58(4):637–646. https://doi.org/10.1053/j.ajkd.2011.03.035 CrossRefPubMedPubMedCentral

33.

Yamaguchi Y, Iwano M, Suzuki D, Nakatani K, Kimura K, Harada K et al (2009) Epithelial–mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. Am J Kidney Dis 54(4):653–664. https://doi.org/10.1053/j.ajkd.2009.05.009 CrossRefPubMed

34.

Salmon AH, Toma I, Sipos A, Muston PR, Harper SJ, Bates DO et al(2007) Evidence for restriction of fluid and solute movement across the glomerular capillary wall by the subpodocytes pace. Am J Physiol Renal Physiol 293(6):F1777–F1786. https://doi.org/10.1152/ajprenal.00187.2007 CrossRefPubMed

35.

Coward RJ, Welsh GI, Yang J, Tasman C, Lennon R, Koziell A et al (2005) The human glomerular podocyte is a novel target for insulin action. Diabetes 54(11):3095–3102CrossRef

36.

Welsh GI, Hale LJ, Eremina V, Jeansson M, Maezawa Y, Lennon R et al (2010) Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 12(4):329–340. https://doi.org/10.1016/j.cmet.2010.08.015 CrossRefPubMedPubMedCentral

37.

Fu J, Lee K, Chuang PY, Liu Z, He JC (2015) Glomerular endothelial cell injury and cross talk in diabetic kidney disease. Am J Physiol Renal Physiol 308(4):F287–F297. https://doi.org/10.1152/ajprenal.00533.2014 CrossRefPubMed

38.

Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B et al (1999) Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48(11):2229–2239CrossRef

39.

Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R (2002) Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51(10):3090–3094CrossRef

40.

Sison K, Eremina V, Baelde H, Min W, Hirashima M, Fantus IG et al (2010) Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 21(10):1691–1701. https://doi.org/10.1681/ASN.2010030295 CrossRefPubMedPubMedCentral

41.

Guan F, Villegas G, Teichman J, Mundel P, Tufro A (2006) Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Renal Physiol 291(2):F422–F428. https://doi.org/10.1152/ajprenal.00448.2005 CrossRefPubMed

42.

Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J et al (2007) Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 13(11):1349–1358. https://doi.org/10.1038/nm1667 CrossRefPubMed

43.

Wu X, Gao Y, Xu L, Dang W, Yan H, Zou D et al (2017) Exosomes from high glucose-treated glomerular endothelial cells trigger the epithelial–mesenchymal transition and dysfunction of podocytes. Sci Rep 7(1):9371. https://doi.org/10.1038/s41598-017-09907-6 CrossRefPubMedPubMedCentral

44.

Satchell SC, Harper SJ, Tooke JE, Kerjaschki D, Saleem MA, Mathieson PW (2002) Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol 13(2):544–550PubMed

45.

Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD et al (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6(4):460–463. https://doi.org/10.1038/74725 CrossRefPubMed

46.

Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277(5322):55–60CrossRef

47.

Dessapt-Baradez C, Woolf AS, White KE, Pan J, Huang JL, Hayward AA et al (2014) Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease. J Am Soc Nephrol 25(1):33–42. https://doi.org/10.1681/ASN.2012121218 CrossRefPubMed

48.

Lim HS, Lip GY, Blann AD (2005) Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 180(1):113–118. https://doi.org/10.1016/j.atherosclerosis.2004.11.004 CrossRefPubMed

49.

Sayyed SG1, Hägele H, Kulkarni OP, Endlich K, Segerer S, Eulberg D et al (2009) Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 52(11):2445–2454. https://doi.org/10.1007/s00125-009-1493-6 CrossRefPubMed

50.

Tufro A (2017) Podocyte shape regulation by semaphorin 3A and MICAL-1. Methods Mol Biol 1493:393–399. https://doi.org/10.1007/978-1-4939-6448-2_28 CrossRefPubMedPubMedCentral

51.

Yuen DA, Stead BE, Zhang Y, White KE, Kabir MG, Thai K et al (2012) eNOS deficiency predisposes podocytes to injury in diabetes. J Am Soc Nephrol 23(11):1810–1823. https://doi.org/10.1681/ASN.2011121170 CrossRefPubMedPubMedCentral

52.

Zanchi A, Moczulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS (2000) Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 57(2):405–413. https://doi.org/10.1046/j.1523-1755.2000.00860.x CrossRefPubMed

53.

Bock F, Shahzad K, Wang H, Stoyanov S, Wolter J, Dong W et al (2013) Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc Natl Acad Sci USA 110(2):648–653. https://doi.org/10.1073/pnas.1218667110 CrossRefPubMed

54.

Zhang M-Z, Wang Y, Paueksakon P, Harris RC (2014) Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. Diabetes 63(6):2063–2072. https://doi.org/10.2337/db13-1279 CrossRefPubMedPubMedCentral

55.

Yin GN, Jin HR, Choi MJ, Limanjaya A, Ghatak K, Minh NN et al (2018) Pericyte-derived Dickkopf2 regenerates damaged penile neurovasculature through an angiopoietin-1-Tie2 pathway. Diabetes 67(6):1149–1161. https://doi.org/10.2337/db17-0833 CrossRefPubMed

56.

Burghardt T, Hochapfel F, Salecker B, Meese C, Gröne HJ, Rachel R et al (2015) Advanced electron microscopic techniques provide a deeper insight into the peculiar features of podocytes. Am J Physiol Renal Physiol 309(12):F1082–F1089. https://doi.org/10.1152/ajprenal.00338.2015 CrossRefPubMed

57.

Musah S, Mammoto A, Ferrante TC, Jeanty SSF, Hirano-Kobayashi M, Mammoto T et al (2017) Mature induced-pluripotent-stem-cell-derived human podocytes reconstitute kidney glomerular-capillary-wall function on a chip. Nat Biomed. https://doi.org/10.1038/s41551-017-0069 CrossRef

58.

Steffes MW, Osterby R, Chavers B, Mauer SM (1989) Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 38(9):1077–1081CrossRef

59.

Lazzeri E, Romagnani P (2015) Podocyte biology: differentiation of parietal epithelial cells into podocytes. Nat Rev Nephrol 11(1):7–8. https://doi.org/10.1038/nrneph.2014.218 CrossRefPubMed

60.

Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG et al (1997) Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99(2):342–348. https://doi.org/10.1172/JCI119163 CrossRefPubMedPubMedCentral

61.

Ziyadeh FN, Wolf G (2008) Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 4(1):39–45CrossRef

62.

Yasuda-Yamahara M, Kume S, Tagawa A, Maegawa H, Uzu T (2015) Emerging role of podocyte autophagy in the progression of diabetic nephropathy. Autophagy 11(12):2385–2386. https://doi.org/10.1080/15548627.2015.1115173 CrossRefPubMedPubMedCentral

63.

Kriz W, Shirato I, Nagata M, LeHir M, Lemley KV (2013) The podocyte’s response to stress: the enigma of foot process effacement. Am J Physiol Renal Physiol 304(4):F333–F347. https://doi.org/10.1152/ajprenal.00478.2012 CrossRefPubMed

64.

Vogelmann SU, Nelson WJ, Myers BD, Lemley KV (2003) Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 285(1):F40–F48. https://doi.org/10.1152/ajprenal.00404.2002 CrossRefPubMedPubMedCentral

65.

Maestroni S, Maestroni A, Dell’Antonio G, Gabellini D, Terzi S, Spinello A et al (2014) Viable podocyturia in healthy individuals: implications for podocytopathies. Am J Kidney Dis 64(6):1003–1005. https://doi.org/10.1053/j.ajkd.2014.08.016 CrossRefPubMed

66.

Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I et al (2000) Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 15(9):1379–1383CrossRef

67.

Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M (2007) Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 56(8):2155–2160. https://doi.org/10.2337/db07-0019 CrossRefPubMed

68.

Weil EJ, Lemley KV, Mason CC, Yee B, Jones LI, Blouch K et al (2012) Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int 82(9):1010–1017. https://doi.org/10.1038/ki.2012.234 CrossRefPubMedPubMedCentral

69.

Conti S, Perico N, Novelli R, Carrara C, Benigni A, Remuzzi G (2018) Early and late scanning electron microscopy findings in diabetic kidney disease. Sci Rep 8(1):4909. https://doi.org/10.1038/s41598-018-23244-2 CrossRefPubMedPubMedCentral

Title: Glomerular endothelial cells versus podocytes as the cellular target in diabetic nephropathy
Authors: Silvia Maestroni
Gianpaolo Zerbini
Publication date: 01-11-2018
Publisher: Springer Milan
Published in: Acta Diabetologica / Issue 11/2018
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-018-1211-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2018

Issue focusing: a new topical collection on diabetic nephropathy

Implementation of effective transition from pediatric to adult diabetes care: epidemiological and clinical characteristics—a pioneering experience in North Africa

Optimization of kidney dysfunction prediction in diabetic kidney disease using targeted metabolomics

The association between cigarette smoking and diabetic nephropathy in Chinese male patients

Association between circulating visfatin and gestational diabetes mellitus: a systematic review and meta-analysis

Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage